Skip to main content

Table 1 Patient baseline characteristics (n = 95)

From: Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation

Characteristic

T group (n = 61)

TC group

(n = 34)

P

Gender

  

0.110

 Male

22(36.07)

18(52.94)

 

 Female

39(63.93)

16(47.06)

 

Age

  

0.440

 < 60

39 (63.93)

19 (55.88)

 

 ≥ 60

22 (36.07)

15 (44.12)

 

Smoking history

  

0.949

 No

47 (77.05)

26 (76.47)

 

 Yes

14 (22.95)

8 (23.53)

 

ECOG PS

  

0.646

 0–1

58 (95.08)

33 (97.06)

 

 2

3 (4.92)

1 (2.94)

 

Histology

  

0.257

 Adenocarcinoma

60 (98.36)

32 (94.12)

 

 Non-adenocarcinoma

1 (1.64)

2 (5.88)

 

Clinical Stage

  

0.719

 IIIB/C

9 (14.75)

6 (17.65)

 

 IV

34 (55.74)

16 (47.06)

 

 IV with BM

18 (29.51)

12 (35.29)

 

Types of EGFR-TKIs

  

0.557

 Gefitinib

41 (67.20)

26 (76.47)

 

 Icotinib

13 (21.31)

5 (14.71)

 

 Erlotinib

2 (3.29)

2 (5.88)

 

 Osimertinib

5 (8.20)

1 (2.94)

 

T790M status

  

0.686

 Negative

17 (27.87)

7 (20.59)

 

 Positive

28 (45.90)

16 (47.06)

 

 Unknow

16 (26.23)

11 (32.35)

 

EGFR mutation

  

0.471

 EGFR19 Del

32(52.46)

16(47.06)

 

 EGFR21 L858R

22(36.07)

16(47.06)

 

 Other mutations

7(11.47)

2(5.88)

 

TP53 mutation

  

0.810

 Exon4

6(9.83)

1(2.94)

 

 Exon5

17(27.87)

11(32.35)

 

 Exon6

4(6.57)

2(5.88)

 

 Exon7

14(22.95)

10(29.41)

 

 Exon8

12(19.67)

5(14.71)

 

 Other mutations

8(13.11)

5(14.71)

 
  1. BM brain metastases, T790M status T790M mutation status at first progression